This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
30 Jul 2012

AstraZeneca Announces Sales Fall in First Half

First-half figures were hit by the loss of exclusivity of the Seroquel (quetiapine) neuroscience franchise, which recorded a 37% fall in sales to $1.78bn.

Pharma giant AstraZeneca reported a 16% fall in sales to US$14bn in the first half of the year, blaming generic competition and tough market conditions for the decline.

 

First-half figures were hit by the loss of exclusivity of the Seroquel (quetiapine) neuroscience franchise, which recorded a 37% fall in sales to $1.78bn. Seroquel IR sales fell by 52% to $1.03bn.

 

Revenues were also down for the gastrointestinal drug Nexium, by 15% to $1.9bn, and breast cancer drug Arimidex (–29% to $291m).

 

The figures were more positive for cholesterol drug Crestor (–2% to $3.09bn) and respiratory drug Symbicort (+1% to $1.52bn).

 

Related News